Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given prolonged administration in patients with solid tumors

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1131-1141

  Rafi, Imran ^a   Boddy, Alan V ^a   Calvete, Joanne A ^a   Taylor, Gordon A ^a   Newell, David R ^a   Bailey, Nigel P ^a   Lind, Michael J ^a   Green, Mark ^a   Hines, John ^a   Johnstone, Amanda ^a   Clendeninn, Neil ^a   Hilary Colvert, A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYURIDINE; NOLATREXED; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0031934445     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1131     Document Type: Article

References (19)

1. Jackman AL, Calvert AH: Folate-based thymidylate synthase inhibitors as anticancer agents. Ann Oncol 6:871-881, 1995
2. Touroutoglou N, Pazdur R: Thymidylate synthase inhibitors. Clin Cancer Res 2:227-243, 1996
3. Rustum YM, Harstrick A, Cao S, et al: Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors. J Clin Oncol 15:389-400, 1997
4. Webber SE, Bleckman TM, Attard J, et al: Design of thymidylate synthase inhibitors using protein crystal-structures - The synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J Med Chem 36:733-746, 1993
5. Webber S, Bartlett CA, Boritzki TJ, et al: AG337, a novel lipophilic thymidylate synthase inhibitor: In vitro and in vivo preclinical studies. Cancer Chemother Pharmacol 37:509-517, 1996
6. Rafi I, Taylor GA, Calvete JA, et al: Clinical pharmacokinetic and pharmacodynamic studies with the non-classical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyndylthio)-quinazolone dihydrochloride (AG337) given by 24 hour continuous intravenous infusion. Clin Cancer Res 1:1275-1284, 1995
7. Yamaoka K, Nakagawa T, Uno T: Application of Akaike''s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175, 1978
8. Balmanno K, Calvete JA, Barnes MJ, et al: Acquired and intrinsic resistance of human colo-rectal cell lines to AG337, a non-classical inhibitor of thymidylate synthase. Br J Cancer 69:9, 1994 (suppl 21)
9. Hughey CT, Barbour KW, Berger FG, et al: Functional-effects of a naturally-occurring amino-acid substitution in human thymidylate synthase. Mol Pharmacol 44:316-323, 1993
10. 10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol 4:1245-4252, 1986
11. Rinaldi DA, Bums HA, Dorr FA, et al: Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13:2842-2850, 1995
12. Clarke SJ, Hanwell J, Debeer M, et al: Phase-1 trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 14:1495-1503, 1996
13. O'Dwyer PJ, Laub PB, DeMaria D, et al: Phase 1 trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clin Cancer Res 2:1685-1692, 1996
14. Hersh EM, Wong VG, Henderson ES, et al: Hepatotoxic effects of methotrexate. Cancer 19:600-606, 1966
15. Loh KK, Cohn A, Kelly K, et al: Phase II trials of THYMITAQ (AG337) in six solid tumor diseases. Proc Am Soc Clin Oncol 15:183, 1996 (abstr 385)
16. Shetty B, Kosa M, Soda K, et al: Pharmacokinetics and tissue distribution of two novel thymidylate synthase inhibitors. AG-331 and AG-337 in the rat. Proc Am Assoc Cancer Res 34:394, 1993 (abstr 2347)
17. Taylor GA, Jackman AL, Calvert AH, et al: Plasma nucleoside and base levels following treatment with the new thymidylate synthetase inhibitor-CB3717. Adv Exp Med Biol 165:379-382, 1984
18. Rafi I, Boddy AF, Taylor GA, et al: A phase I clinical study of the novel antifolate AG337 given by 5 day oral administration. Proc Am Assoc Cancer Res 36:178, 1996 (abstr 1218)
19. Hughes AN, Griffin MJ, Rafi I, et al: Absorption of the TS inhibitor AG337 (THYMITAQ) when administered orally in the fed and fasted states. Proc Am Assoc Cancer Res 38:615, 1997 (abstr 4131)